SCHEMBL3978787

SCHEMBL3978787

CN(Cc1ccc(-c2ccc(C#N)cc2)nc1)C1CCN(C(=O)O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.48
MKNK2 Q9HBH9 2/20 0.48
DPP4 P27487 1/20 0.44
CYP11B1 P15538 1/20 0.41
HSD11B1 P28845 3/20 0.41
CCR5 P51681 1/20 0.41
MCHR1 Q99705 1/20 0.40
PRKAA2 P54646 1/20 0.40
CTSC P53634 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
KDM1A O60341 2/20 0.38
SYK P43405 1/20 0.38
ITK Q08881 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FLT3 P36888 1/20 0.37
TYRO3 Q06418 1/20 0.37
MERTK Q12866 1/20 0.37
GAS6 Q14393 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190996 0.87 GPR119 (0.56) MKNK1MKNK2GPR119
SCHEMBL3980484 0.85 GPR119 (0.45) MCHR1GPR119NPC1RAB9ASMN1; SMN2
SCHEMBL3984054 0.84 GPR119 (0.48) GPR119
SCHEMBL3980096 0.82 USP30 (0.46) MKNK1MKNK2DPP4HSD11B1MCHR1
SCHEMBL3978505 0.81 HRH3 (0.45) MKNK1MKNK2NPC1RAB9ASMN1; SMN2
SCHEMBL3984660 0.77 KMT2A (0.46)
SCHEMBL3983148 0.76 GPR119 (0.47) MCHR1GPR119NPC1RAB9ASMN1; SMN2
SCHEMBL3979497 0.76 GPR119 (0.45) CTSCGPR119
SCHEMBL12548474 0.74 GPR119 (0.56) GPR119
SCHEMBL5079950 0.74 GPR119 (0.47) MKNK1MKNK2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2059516-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (publ) (SE) 2009-05-20 EP claimed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US claimed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO claimed
EP-2059516-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (publ) (SE) 2009-05-20 EP disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 MKNK1 3949/4885MKNK2 3854/4885DPP4 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.